luminol has been researched along with Spinal Cord Injuries in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akakın, D; Çevik, Ö; Erşahin, M; Özbay, L; Şener, A; Şener, G; Yegen, BC | 1 |
| Bednar, MM; Gross, CE; Howard, DB; Lynn, M | 1 |
2 other study(ies) available for luminol and Spinal Cord Injuries
| Article | Year |
|---|---|
Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
Topics: Acetates; Animals; Behavior, Animal; Caspase 3; Cyclopropanes; Down-Regulation; Glutathione; Interleukin-1beta; Leukotriene Antagonists; Leukotriene B4; Lipid Peroxidation; Luminescent Measurements; Luminol; Malondialdehyde; Neutrophil Infiltration; Neutrophils; Oxidative Stress; Peroxidase; Quinolines; Rats; Rats, Wistar; Spinal Cord; Spinal Cord Injuries; Sulfides; Tumor Necrosis Factor-alpha; Urinary Bladder | 2012 |
Neutrophil activation in acute human central nervous system injury.
Topics: Adult; Aged; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Craniocerebral Trauma; Female; Humans; Ischemic Attack, Transient; Luminescent Measurements; Luminol; Male; Middle Aged; Neutrophil Activation; Spinal Cord Injuries; Time Factors | 1997 |